<p>Milestone Pharmaceuticals（納斯達克代碼：MIST - 獲取免費報告）在週一發佈給投資者的研究報告中，被 TD Cowen 的股票研究人員從 “持有” 評級上調至 “買入” 評級。該券商目前對該股票的目標價為 8.00 美元。TD Cowen 的目標價暗示該股票相較於之前的收盤價有 239.70% 的潛在上漲空間。</p>
<p>MIST 還受到其他幾份報告的關注。Weiss Ratings 在 12 月 1 日的報告中重申了對 Milestone Pharmaceuticals 股票的 “賣出（e+）” 評級。Wells Fargo &amp; Company 在 9 月 11 日的研究報告中開始覆蓋 Milestone Pharmaceuticals，給予 “增持” 評級和 4.00 美元的目標價。最後，Wall Street Zen 在週六的報告中將 Milestone Pharmaceuticals 的股票評級從 “持有” 下調至 “賣出”。三位分析師給予該股票 “買入” 評級，兩位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “持有”，共識目標價為 5.67 美元。</p>
<p><strong>查看我們最新的 MIST 股票報告</strong></p>
<h2>Milestone Pharmaceuticals 股價下跌 2.3%</h2>
<p>週一，MIST 股票下跌 0.06 美元，報 2.36 美元。該公司的股票交易量為 42,738,590 股，而其平均交易量為 2,079,424 股。該公司的市值為 2.0058 億美元，市盈率為-2.79，貝塔值為 0.40。該公司的 50 日簡單移動平均為 2.18 美元，200 日簡單移動平均為 1.91 美元。Milestone Pharmaceuticals 的 12 個月低點為 0.63 美元，12 個月高點為 3.06 美元。該公司的債務與股本比率為 2.74，速動比率為 8.24，流動比率為 8.24。</p>
<p>Milestone Pharmaceuticals（納斯達克代碼：MIST - 獲取免費報告）最近在 11 月 12 日發佈了季度財報。該公司報告的每股收益為-0.12 美元，超出市場共識預期的-0.17 美元，超出幅度為 0.05 美元。整體來看，研究分析師預測 Milestone Pharmaceuticals 在當前年度的每股收益為-0.62 美元。</p>
<h2>機構投資者對 Milestone Pharmaceuticals 的看法</h2>
<p>幾家對沖基金和其他機構投資者最近調整了對 MIST 的持倉。Propel Bio Management LLC 在第三季度將其在 Milestone Pharmaceuticals 的持倉增加了 186.1%。Propel Bio Management LLC 目前擁有 5,124,890 股該公司股票，價值 10,250,000 美元，此前在上個季度又購買了 3,333,333 股。Orbimed Advisors LLC 在第三季度購買了 Milestone Pharmaceuticals 的新頭寸，價值約為 6,444,000 美元。Simplify Asset Management Inc.在第三季度將其在 Milestone Pharmaceuticals 的持倉增加了 186.2%。Simplify Asset Management Inc.目前擁有 2,832,974 股該公司股票，價值 5,666,000 美元，此前在上個季度又收購了 1,842,974 股。Pathstone Holdings LLC 在第三季度購買了 Milestone Pharmaceuticals 的新股份，價值約為 2,000,000 美元。最後，Boxer Capital Management LLC 在第三季度購買了 Milestone Pharmaceuticals 的新頭寸，價值約為 1,333,000 美元。目前 86.18% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>Milestone Pharmaceuticals 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Milestone Pharmaceuticals Inc 是一家生物製藥公司，專注於心血管藥物的開發和商業化。該公司的主要產品候選藥物是 etripamil，一種新型且有效的鈣通道阻滯劑，目前正在美國和加拿大進行治療陣發性室上性心動過速的第三階段臨牀試驗；並在進行治療房顫和快速心室率的第二階段臨牀試驗。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Milestone Pharmaceuticals</li>
<li>羅素 2000 指數，投資者如何利用它進行盈利交易</li>
<li>三家公司將大現金流轉化為更大的股東收益</li>
<li>什麼是分紅成就者？簡介</li>
<li>GOOGL 的不可阻擋的勢頭推動價格目標創下新高</li>
<li>現在購買的三隻沃倫·巴菲特股票</li>
<li>三隻被低估的機器人股票，準備迎來鉅額收益</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUlTVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUlTVA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Milestone Pharmaceuticals 嗎？</h2>
<p>在你考慮 Milestone Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Milestone Pharmaceuticals 並不在名單上。</p>
<p>雖然 Milestone Pharmaceuticals 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

MIST

<p>TD Cowen 將 Milestone Pharmaceuticals（NASDAQ:MIST）的評級從 “持有” 上調至 “買入”，設定目標價為 8.00 美元，暗示上漲空間為 239.70%。儘管其他分析師的評級不一，該股票的共識評級為 “持有”，目標價為 5.67 美元。機構投資者顯著增加了持股。Milestone 專注於心血管藥物，其主要產品 etripamil 正在進行臨牀試驗。該股票下跌 2.3%，報 2.36 美元，市值為 2.0058 億美元</p>

<p>Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) was upgraded by equities researchers at TD Cowen from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note issued to investors on Monday. The brokerage currently has a $8.00 target price on the stock. TD Cowen's price target suggests a potential upside of 239.70% from the stock's previous close.</p>
<div class="lb-trans"><p>Milestone Pharmaceuticals（納斯達克代碼：MIST - 獲取免費報告）在週一發佈給投資者的研究報告中，被 TD Cowen 的股票研究人員從 “持有” 評級上調至 “買入” 評級。該券商目前對該股票的目標價為 8.00 美元。TD Cowen 的目標價暗示該股票相較於之前的收盤價有 239.70% 的潛在上漲空間。</p>
</div><p>MIST has been the subject of several other reports. Weiss Ratings restated a &#34;sell (e+)&#34; rating on shares of Milestone Pharmaceuticals in a report on Monday, December 1st. Wells Fargo &amp; Company initiated coverage on Milestone Pharmaceuticals in a research note on Thursday, September 11th. They issued an &#34;overweight&#34; rating and a $4.00 price target on the stock. Finally, Wall Street Zen lowered shares of Milestone Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of &#34;Hold&#34; and a consensus price target of $5.67.</p>
<div class="lb-trans"><p>MIST 還受到其他幾份報告的關注。Weiss Ratings 在 12 月 1 日的報告中重申了對 Milestone Pharmaceuticals 股票的 “賣出（e+）” 評級。Wells Fargo &amp; Company 在 9 月 11 日的研究報告中開始覆蓋 Milestone Pharmaceuticals，給予 “增持” 評級和 4.00 美元的目標價。最後，Wall Street Zen 在週六的報告中將 Milestone Pharmaceuticals 的股票評級從 “持有” 下調至 “賣出”。三位分析師給予該股票 “買入” 評級，兩位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “持有”，共識目標價為 5.67 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on MIST</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 MIST 股票報告</strong></p>
</div><h2>Milestone Pharmaceuticals Trading Down 2.3%</h2>
<div class="lb-trans"><h2>Milestone Pharmaceuticals 股價下跌 2.3%</h2>
</div><p>MIST stock traded down $0.06 on Monday, reaching $2.36. The company's stock had a trading volume of 42,738,590 shares, compared to its average volume of 2,079,424. The firm has a market cap of $200.58 million, a PE ratio of -2.79 and a beta of 0.40. The business has a fifty day simple moving average of $2.18 and a two-hundred day simple moving average of $1.91. Milestone Pharmaceuticals has a 12-month low of $0.63 and a 12-month high of $3.06. The company has a debt-to-equity ratio of 2.74, a quick ratio of 8.24 and a current ratio of 8.24.</p>
<div class="lb-trans"><p>週一，MIST 股票下跌 0.06 美元，報 2.36 美元。該公司的股票交易量為 42,738,590 股，而其平均交易量為 2,079,424 股。該公司的市值為 2.0058 億美元，市盈率為-2.79，貝塔值為 0.40。該公司的 50 日簡單移動平均為 2.18 美元，200 日簡單移動平均為 1.91 美元。Milestone Pharmaceuticals 的 12 個月低點為 0.63 美元，12 個月高點為 3.06 美元。該公司的債務與股本比率為 2.74，速動比率為 8.24，流動比率為 8.24。</p>
</div><p>Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.05. As a group, research analysts forecast that Milestone Pharmaceuticals will post -0.62 EPS for the current year.</p>
<div class="lb-trans"><p>Milestone Pharmaceuticals（納斯達克代碼：MIST - 獲取免費報告）最近在 11 月 12 日發佈了季度財報。該公司報告的每股收益為-0.12 美元，超出市場共識預期的-0.17 美元，超出幅度為 0.05 美元。整體來看，研究分析師預測 Milestone Pharmaceuticals 在當前年度的每股收益為-0.62 美元。</p>
</div><h2>Institutional Investors Weigh In On Milestone Pharmaceuticals</h2>
<div class="lb-trans"><h2>機構投資者對 Milestone Pharmaceuticals 的看法</h2>
</div><p>Several hedge funds and other institutional investors have recently modified their holdings of MIST. Propel Bio Management LLC lifted its position in Milestone Pharmaceuticals by 186.1% during the third quarter. Propel Bio Management LLC now owns 5,124,890 shares of the company's stock valued at $10,250,000 after purchasing an additional 3,333,333 shares in the last quarter. Orbimed Advisors LLC bought a new position in shares of Milestone Pharmaceuticals during the 3rd quarter valued at approximately $6,444,000. Simplify Asset Management Inc. increased its holdings in Milestone Pharmaceuticals by 186.2% in the 3rd quarter. Simplify Asset Management Inc. now owns 2,832,974 shares of the company's stock worth $5,666,000 after acquiring an additional 1,842,974 shares in the last quarter. Pathstone Holdings LLC bought a new stake in Milestone Pharmaceuticals during the 3rd quarter worth approximately $2,000,000. Finally, Boxer Capital Management LLC purchased a new position in Milestone Pharmaceuticals during the third quarter valued at approximately $1,333,000. 86.18% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>幾家對沖基金和其他機構投資者最近調整了對 MIST 的持倉。Propel Bio Management LLC 在第三季度將其在 Milestone Pharmaceuticals 的持倉增加了 186.1%。Propel Bio Management LLC 目前擁有 5,124,890 股該公司股票，價值 10,250,000 美元，此前在上個季度又購買了 3,333,333 股。Orbimed Advisors LLC 在第三季度購買了 Milestone Pharmaceuticals 的新頭寸，價值約為 6,444,000 美元。Simplify Asset Management Inc.在第三季度將其在 Milestone Pharmaceuticals 的持倉增加了 186.2%。Simplify Asset Management Inc.目前擁有 2,832,974 股該公司股票，價值 5,666,000 美元，此前在上個季度又收購了 1,842,974 股。Pathstone Holdings LLC 在第三季度購買了 Milestone Pharmaceuticals 的新股份，價值約為 2,000,000 美元。最後，Boxer Capital Management LLC 在第三季度購買了 Milestone Pharmaceuticals 的新頭寸，價值約為 1,333,000 美元。目前 86.18% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Milestone Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Milestone Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.</p>
<div class="lb-trans"><p>Milestone Pharmaceuticals Inc 是一家生物製藥公司，專注於心血管藥物的開發和商業化。該公司的主要產品候選藥物是 etripamil，一種新型且有效的鈣通道阻滯劑，目前正在美國和加拿大進行治療陣發性室上性心動過速的第三階段臨牀試驗；並在進行治療房顫和快速心室率的第二階段臨牀試驗。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Milestone Pharmaceuticals</li>
<li>Russell 2000 Index, How Investors Use it For Profitable Trading</li>
<li>3 Companies Turning Big Cash Flow Into Bigger Shareholder Gains</li>
<li>What Are Dividend Achievers? An Introduction</li>
<li>GOOGL's Unstoppable Momentum Drives Price Targets to Record Highs</li>
<li>3 Warren Buffett Stocks to Buy Now</li>
<li>3 Underrated Robotics Stocks Poised for Huge Gains</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Milestone Pharmaceuticals</li>
<li>羅素 2000 指數，投資者如何利用它進行盈利交易</li>
<li>三家公司將大現金流轉化為更大的股東收益</li>
<li>什麼是分紅成就者？簡介</li>
<li>GOOGL 的不可阻擋的勢頭推動價格目標創下新高</li>
<li>現在購買的三隻沃倫·巴菲特股票</li>
<li>三隻被低估的機器人股票，準備迎來鉅額收益</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUlTVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=MIST"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Milestone Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Milestone Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Milestone Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Milestone Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Milestone Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Milestone Pharmaceuticals 並不在名單上。</p>
</div><p>While Milestone Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Milestone Pharmaceuticals 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Milestone Pharmaceuticals（納斯達克代碼：MIST）在 TD Cowen 被上調至買入評級